FDA Pediatric Therapeutics Office Could Fall Under ORM Purview
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Pediatric Therapeutics would be located within the Office of Review Management under proposed organizational changes at the agency.
You may also be interested in...
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
FDA restructuring
Office of Pediatric Drug Development & Special Initiatives, forming Oct. 1, will be headed by ODE IV Director Dianne Murphy, MD. Division of Special Pathogenic & Immunologic Drug Products Director Mark Goldberger, MD, will take over as ODE IV acting director. The office will assist with pediatric drug policy and regulatory support, handle "initiatives related to the study and labeling of drugs in pregnancy" and serve as a liaison with external pediatric advocacy groups, CDER says. Originally slated to be the Office of Pediatric Therapeutics, the office reflects the upsurge in pediatric clinical trials following passage of FDAMA's pediatric exclusivity provisions (1"The Tan Sheet" July 16, p. 16)
Pediatric Labeling Negotiations Limited To Six Months In Reauthorization Bill
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.